Header Logo

Celalettin Ustun

Concepts (94)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hematopoietic Stem Cell Transplantation
20
2023
109
8.280
Why?
Graft vs Host Disease
11
2023
50
5.510
Why?
Leukemia, Myeloid, Acute
7
2022
49
2.800
Why?
Transplantation Conditioning
8
2022
39
0.980
Why?
Cord Blood Stem Cell Transplantation
2
2021
6
0.890
Why?
Mycoses
1
2023
20
0.880
Why?
Bacterial Infections
1
2023
50
0.870
Why?
Mastocytosis, Systemic
1
2022
6
0.840
Why?
Hematologic Neoplasms
2
2020
17
0.830
Why?
Calcineurin Inhibitors
4
2023
15
0.810
Why?
Roseolovirus Infections
1
2021
4
0.750
Why?
Core Binding Factor beta Subunit
1
2020
2
0.730
Why?
Humans
26
2023
25227
0.730
Why?
Oncogene Proteins, Fusion
1
2020
9
0.730
Why?
Biosimilar Pharmaceuticals
1
2020
3
0.710
Why?
Infliximab
1
2020
16
0.710
Why?
Granulocyte Precursor Cells
1
2019
3
0.690
Why?
Lymphoma, Large B-Cell, Diffuse
1
2019
28
0.670
Why?
Neoplasms
1
2022
213
0.660
Why?
Tumor Necrosis Factor-alpha
1
2020
174
0.660
Why?
Retrospective Studies
7
2023
3105
0.510
Why?
Recurrence
5
2023
291
0.480
Why?
Cyclophosphamide
2
2023
44
0.450
Why?
Transplantation, Homologous
6
2020
249
0.410
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2021
11
0.360
Why?
Child, Preschool
2
2023
588
0.350
Why?
Myelodysplastic Syndromes
2
2022
31
0.340
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
2020
8
0.340
Why?
Middle Aged
8
2022
8144
0.290
Why?
Adult
9
2022
7089
0.270
Why?
Risk Factors
4
2020
2175
0.260
Why?
Disease-Free Survival
2
2022
152
0.250
Why?
Aged
7
2023
8432
0.230
Why?
Tacrolimus
2
2021
16
0.230
Why?
Saccharomyces cerevisiae
1
2023
19
0.220
Why?
Scedosporium
1
2023
4
0.220
Why?
Tissue Donors
1
2023
68
0.210
Why?
Young Adult
5
2020
1751
0.210
Why?
Male
6
2022
13573
0.210
Why?
Pyrroles
1
2022
23
0.210
Why?
Whole-Body Irradiation
1
2022
10
0.210
Why?
Vidarabine
1
2022
9
0.200
Why?
Liver Cirrhosis
1
2022
40
0.200
Why?
Pyrazoles
1
2022
47
0.200
Why?
Immunosuppressive Agents
2
2020
119
0.200
Why?
Adolescent
4
2020
1998
0.190
Why?
Incidence
1
2023
669
0.190
Why?
Pain
2
2021
365
0.180
Why?
Leukemia, Myeloid, Chronic-Phase
1
2020
1
0.180
Why?
Leukocyte Count
1
2020
62
0.180
Why?
Prognosis
2
2020
727
0.180
Why?
Calcineurin
1
2020
9
0.180
Why?
Cell Count
1
2020
67
0.180
Why?
Pyrazines
1
2019
10
0.170
Why?
Gastrointestinal Tract
1
2020
50
0.170
Why?
Aniline Compounds
1
2019
39
0.170
Why?
Drug Resistance
1
2019
41
0.170
Why?
Acute Disease
1
2020
185
0.170
Why?
Steroids
1
2019
23
0.170
Why?
Typhlitis
1
2019
2
0.160
Why?
Mucositis
1
2019
4
0.160
Why?
Lung Diseases
1
2019
40
0.160
Why?
Coronavirus Infections
1
2020
81
0.160
Why?
Pneumonia, Viral
1
2020
84
0.160
Why?
Liver Diseases
1
2019
30
0.160
Why?
Allografts
1
2019
187
0.150
Why?
Pandemics
1
2020
233
0.150
Why?
Female
5
2023
13874
0.150
Why?
Age Factors
1
2020
721
0.150
Why?
Leukemia, Myelomonocytic, Chronic
1
2017
2
0.140
Why?
Child
1
2020
1232
0.140
Why?
Treatment Outcome
2
2020
3147
0.120
Why?
Chromosome Aberrations
2
2021
13
0.090
Why?
Remission Induction
2
2022
86
0.080
Why?
Survival Rate
2
2018
310
0.070
Why?
Survival Analysis
2
2017
233
0.060
Why?
Toes
1
2023
6
0.060
Why?
Voriconazole
1
2023
11
0.050
Why?
Antifungal Agents
1
2023
34
0.050
Why?
Cohort Studies
2
2022
1758
0.050
Why?
Unrelated Donors
1
2022
5
0.050
Why?
Siblings
1
2022
17
0.050
Why?
Neoplasm Recurrence, Local
1
2022
182
0.050
Why?
Blast Crisis
1
2020
1
0.050
Why?
Cyclosporine
1
2020
12
0.040
Why?
Stem Cell Transplantation
1
2020
39
0.040
Why?
Betacoronavirus
1
2020
69
0.040
Why?
Alemtuzumab
1
2018
5
0.040
Why?
Multivariate Analysis
1
2018
278
0.040
Why?
Proportional Hazards Models
1
2018
315
0.040
Why?
Probability
1
2017
84
0.040
Why?
Bone Marrow Transplantation
1
2017
22
0.040
Why?
Risk Assessment
1
2017
597
0.030
Why?
Prospective Studies
1
2018
1595
0.030
Why?
Ustun's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (94)
Explore
_
Co-Authors (10)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_